Subscribe To
NRSN / NeuroSense: A Hold Ahead Of Phase 2b ALS Data
NRSN News
By Seeking Alpha
October 6, 2023
NeuroSense: A Hold Ahead Of Phase 2b ALS Data
NeuroSense Therapeutics will report Phase 2b trial data for its ALS drug candidate, PrimeC, in Q4 2023. Topline data of this trial may well be the com more_horizontal
By InvestorPlace
January 19, 2023
Why Is NeuroSense (NRSN) Stock Up 98% Today?
NeuroSense (NASDAQ: NRSN ) stock is taking off on Thursday as investors react to data from a biomarker study concerning Alzheimer's disease ( AD ). Th more_horizontal
By InvestorPlace
June 27, 2022
NeuroSense Therapeutics (NRSN) Stock Pops on Positive ALS Study Results
NRSN stock is getting plenty of attention today and a bid to the tune of more than 70% in the wake of positive clinical results. The post NeuroSense T more_horizontal
By Invezz
March 22, 2022
Neurosense multiplies investor value 3X. Buy the penny stock and wait
Neurosense Therapeutics Ltd (NASDAQ:NRSN) tripled market value in a day. This was after announcing approval by the US Food and Drugs Authority to adva more_horizontal
By InvestorPlace
March 21, 2022
Why Is NeuroSense Therapeutics (NRSN) Stock Up 300% Today?
A thumbs up from the FDA has NRSN stock surging. Here's what this victory means for NeuroSense and for investors. more_horizontal
By PennyStocks
March 21, 2022
Hottest Penny Stocks To Watch as March Comes to an End
Check these three penny stocks out for your watchlist right now The post Hottest Penny Stocks To Watch as March Comes to an End appeared first on Pe more_horizontal
By Benzinga
March 21, 2022
Why NeuroSense Shares Are Soaring Today
NeuroSense Therapeutics Ltd (NASDAQ: NRSN) shares are soaring Monday after the company announced it received U.S. Food and Drug Administration cle more_horizontal
By PRNewsWire
January 31, 2022
NeuroSense Therapeutics to Present at BIO CEO & Investor Conference
CAMBRIDGE, Mass., Jan. 31, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. more_horizontal